Prime editing is a next-generation CRISPR gene editing technology that offers unprecedented precision for making precise genetic modifications without requiring double-strand DNA breaks. This mechanism page explores how prime editing is being developed as a therapeutic approach for neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS).
Prime editing was first described by Liu et al. in 2019 and represents a major advancement over traditional CRISPR-Cas9 systems. Unlike conventional CRISPR approaches that rely on double-strand breaks and cellular repair pathways, prime editing directly writes new genetic information into the genome with high precision and minimal byproducts.
The technology has shown promise for treating hereditary neurodegenerative diseases by enabling:
- Precise correction of pathogenic point mutations
- Insertion of protective genetic variants
- Targeted epigenetic modifications
- All 12 types of point mutations (transitions and transversions)
Prime editing utilizes a fusion protein consisting of:
- Cas9 nickase (nCas9) — A modified Cas9 that nicks only one DNA strand rather than creating double-strand breaks
- Reverse transcriptase (RT) — An enzyme that directly copies RNA sequences into DNA
- Prime editing guide RNA (pegRNA) — A specialized RNA that serves dual roles as both a targeting guide and a template for editing
The prime editing mechanism proceeds through several steps:
- Target recognition: The nCas9-RT fusion protein complexed with pegRNA recognizes and binds to the target DNA sequence
- Nicking: The nCas9 component nicks the non-target DNA strand, creating a 3' end
- Prime binding: The 3' end of the nicked DNA hybridizes with the primer binding site (PBS) on the pegRNA
- Reverse transcription: The reverse transcriptase uses the pegRNA template to synthesize the edited DNA sequence directly onto the nicked strand
- Resolution: The flaps are resolved, incorporating the edited sequence into the genome
The pegRNA contains three critical regions:
- Spacer sequence (20 nt) — Directs the complex to the target site
- Primer binding site (PBS) (10-15 nt) — Initiates reverse transcription
- RTT template (10-20 nt) — Carries the desired edit
| Feature |
Traditional CRISPR-Cas9 |
Prime Editing |
| Double-strand breaks |
Required |
None |
| Off-target effects |
Higher |
Significantly reduced |
| Precision |
Lower |
Very high |
| Edit types |
Limited to insertions/deletions |
All 12 point mutations |
| Byproducts |
Indels common |
Minimal indels |
| Cellular repair |
HDR (low efficiency) |
Direct writing |
Key advantages include:
- No double-strand breaks: Eliminates risk of large chromosomal rearrangements
- Precision editing: Can install any of the 12 possible point mutations with high fidelity
- Reduced off-target activity: Studies show 10-100x fewer off-target edits compared to conventional Cas9
- Versatility: Can perform insertions, deletions, and all types of base substitutions
Mutations in the APP (Amyloid Precursor Protein) gene can lead to increased amyloid-beta production, a hallmark of AD. Prime editing offers the ability to:
- Correct pathogenic APP mutations (e.g., Swedish mutation, London mutation)
- Reduce amyloidogenic processing by modifying cleavage sites
- Introduce protective variants
The APOE gene has three common alleles (ε2, ε3, ε4) with varying AD risk:
- ε4 — Major genetic risk factor for late-onset AD
- ε2 — Protective against AD
Prime editing can convert high-risk APOE4 alleles to APOE3 or APOE2, potentially reducing AD risk. Research has shown adenine base editing can convert APOE4 to APOE3; prime editing could achieve similar or broader conversions.
Prime editing enables:
- Direct correction of pathogenic mutations in early-onset AD
- Engineering of APP promoter regions to reduce expression
- Creation of induced pluripotent stem cell (iPSC) models for drug screening
Heterozygous mutations in the GBA gene are the most common genetic risk factor for PD. Prime editing can:
- Correct pathogenic GBA mutations
- Restore glucocerebrosidase enzymatic activity
- Reduce alpha-synuclein aggregation associated with GBA deficiency
LRRK2 mutations are a major cause of familial PD. Prime editing offers:
- Correction of pathogenic LRRK2 variants (G2019S, R1441C/H/G)
- Modulation of LRRK2 kinase activity through precise amino acid changes
- Generation of isogenic cell models for studying LRRK2 pathology
The SNCA gene encodes alpha-synuclein, whose aggregation is central to PD pathogenesis. Prime editing approaches include:
- Correcting SNCA mutations (A53T, A30P, E46K)
- Reducing SNCA expression through promoter modifications
- Introducing protective variants
Mutations in SOD1 cause approximately 20% of familial ALS cases. Prime editing can:
- Correct over 190 known SOD1 pathogenic mutations
- Reduce mutant SOD1 protein aggregation
- Restore normal SOD1 enzymatic function
Hexanucleotide repeat expansions in C9orf72 are the most common cause of familial ALS and FTD. Prime editing offers:
- Reduction of repeat expansions
- Targeting of toxic dipeptide repeat proteins (DPRs)
- Modulation of C9orf72 expression
FUS mutations cause a subset of aggressive ALS cases. Prime editing enables:
- Correction of pathogenic FUS mutations
- Restoration of proper RNA splicing
- Reduction of FUS protein mislocalization
Adeno-associated virus (AAV) vectors are the leading delivery platform for CNS gene therapy, but face significant limitations:
- Size limit: AAV has a ~4.7 kb packaging capacity, insufficient for the nCas9-RT fusion (~5.2 kb)
- Solution: Split-intein systems, smaller Cas9 orthologs (SaCas9, Cas12f), or dual-AAV approaches
| Method |
Advantages |
Disadvantages |
| AAV |
Long-term expression, low immunogenicity |
Size constraints, limited packaging |
| Lentivirus |
Larger capacity, integration |
Risk of insertional mutagenesis |
| Lipid nanoparticles (LNPs) |
Safe, scalable |
Transient expression |
| Virus-like particles (VLPs) |
No genome, transient |
Lower targeting efficiency |
| Electroporation |
High efficiency (in vitro) |
Tissue damage |
- Intrathecal delivery: Direct injection into cerebrospinal fluid
- Convection-enhanced delivery: Pressure-driven infusion into brain tissue
- Systemic delivery with BBB-crossing peptides: Peripheral administration with targeting ligands
- Focused ultrasound: Temporary BBB opening for enhanced CNS penetration
Multiple research groups are advancing prime editing for neurodegenerative diseases:
- Proof-of-concept studies: Demonstrated efficient editing in neurons derived from patient iPSCs
- Animal models: Prime editing in mouse models of AD, PD, and ALS showing therapeutic benefit
- Delivery optimization: Development of CNS-targeted delivery systems
- 2019: Prime editing first described (Liu et al.)
- 2020-2022: Base editing and prime editing applied to neurodegenerative disease models
- 2023: Reviews highlight prime editing potential for hereditary neurological disorders
- 2024-2025: Advanced delivery systems in preclinical development
¶ Company Landscape
Several biotechnology companies are developing prime editing therapies:
- Prime Medicine — Lead program in liver diseases, expanding to CNS
- Beam Therapeutics — Base editing focus, developing dual base/prime editing
- Verve Therapeutics — Cardiovascular applications, technology applicable to CNS
- Excision BioTherapeutics — CRISPR-based approaches for CNS disorders
Key academic researchers advancing prime editing for neurological diseases include:
- Keith J. Liu — Pioneer of prime editing technology (Harvard/MIT)
- David R. Liu — Developed prime editing and base editing (Broad Institute)
- Jean-Pierre Tremblay — Research on prime editing for neurodegenerative diseases
- Katherine Godbout — Authored comprehensive review of prime editing for neurodegenerative diseases
Prime editing represents a promising approach for treating hereditary neurodegenerative diseases, with several advantages over existing gene therapy modalities:
- Precision: Ability to make exact genetic corrections without off-target effects
- Versatility: Can address all types of point mutations
- Safety: Avoids double-strand breaks and chromosomal rearrangements
- Durability: Potential for long-lasting therapeutic benefit
¶ Challenges Remaining
- Delivery: Efficient CNS delivery remains the primary obstacle
- Efficiency: Editing efficiency in post-mitotic neurons requires optimization
- Immune response: Pre-existing immunity to Cas9 proteins
- Clinical translation: Regulatory pathway for prime editing therapies
- Development of compact prime editing systems for AAV delivery
- Combination with gene delivery optimization for CNS targeting
- Clinical trials for hereditary neurological diseases with well-defined genetic targets
- Title — Journal (Year). PMID: XXXXX.